Walter E. Aulitzky

The FAP × CD3 bispecific antibody OMTX305 induces T cell–mediated antitumor effects in patient-derived ex vivo models of solid tumors

Julia Thiel, Jan A. Schlegel, Chunguang Liang, Thomas E. Mürdter et autres

Within solid tumors, stromal barriers and immune exclusion limit the success of immunotherapies. Thus, novel therapeutic approaches are required to remodel the tumor-supportive microenvironment and enhance therapeutic responses. We developed a bispecific, trivalent Fab-eIg T cell engager (OMTX305) targeting fibroblast activation protein …

de, es (code pays fourni par la source)

Abstract 1602: Advancing personalized medicine using precision-cut tumor slices - assessing individual responses to immunotherapy in the tumor microenvironment

Julia Thiel, Jan A. Schlegel, Adrian Kneer, Sascha Dreher et autres

Abstract Immunotherapies have emerged as a promising pillar for cancer therapy. However, due to their reliance on the individual, complex and dynamic tumor microenvironment, treatment success remains limited to a subset of patients. A deeper understanding of the response of individual tumors …

de (code pays fourni par la source)

Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients

Jonas S. Heitmann, Susanne Jung, Marcel Wacker, Yacine Maringer et autres

Cancer peptide vaccination represents a promising therapeutic approach, but has been hampered by lack of suitable antigens and restricted applicability due to different HLA backgrounds of individual patients. We here introduce a novel warehouse-based concept for composition of personalized peptide vaccines and …

de (code pays fourni par la source)

BCL-2 and BOK regulate apoptosis by interaction of their C-terminal transmembrane domains

Tobias B. Beigl, Alexander Paul, Thomas Fellmeth, Dang Quan Nguyen et autres

The Bcl-2 family controls apoptosis by direct interactions of pro- and anti-apoptotic proteins. The principle mechanism is binding of the BH3 domain of pro-apoptotic proteins to the hydrophobic groove of anti-apoptotic siblings, which is therapeutically exploited by approved BH3-mimetic anti-cancer drugs. Evidence …

de, ca (code pays fourni par la source)

BCL-2 and BOK regulate apoptosis by interaction of their C-terminal transmembrane domains

Tobias B. Beigl, Alexander Paul, Thomas Fellmeth, Dang Quan Nguyen et autres

Abstract The Bcl-2 family controls apoptosis by direct interactions of pro- and anti-apoptotic proteins. The principle mechanism is binding of the BH3 domain of pro-apoptotic proteins to the hydrophobic groove of anti-apoptotic siblings, which is therapeutically exploited by approved BH3-mimetic anti-cancer drugs. …

de, ca, nl (code pays fourni par la source)

ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC

Kathrin Böpple, Yaara Oren, Whitney S. Henry, Meng Dong et autres

High-grade serous ovarian cancer (HGSOC) represents the most common and lethal subtype of ovarian cancer. Despite initial response to platinum-based standard therapy, patients commonly suffer from relapse that likely originates from drug-tolerant persister (DTP) cells. We generated isogenic clones of treatment-naïve and …

de, il, us (code pays fourni par la source)

Abstract 639: Evaluation of individual drug response in tumor microenvironment to cisplatin treatment in precision-cut tumor slices of ovarian cancer

Julia Thiel, Adrian Kneer, Weimeng Yu, Bernd E. Winkler et autres

Abstract Ovarian cancer is a complex and heterogeneous disease and the major cause of death among women with gynecological cancers. While patients usually respond well to the platinum-based first-line chemotherapy, the disease often becomes increasingly resistant to the treatment. The tumor microenvironment …

de (code pays fourni par la source)

Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3

Mark J. Levis, Mehdi Hamadani, Brent R. Logan, Richard John Jones et autres

PURPOSE Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of FLT3 ( FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. …

us, kr, de, jp, gb, il, au (code pays fourni par la source)

Abstract 2020: Nascent proteome analysis of drug response in precision-cut tumor slices

Julia Thiel, Lina-Marie Wagner, Karim Aljakouch, Julia B. Schüler et autres

Abstract The complex and dynamic microenvironment of tumors influences their development, progression, and response to therapy. In addition to cancer cells, solid tumors consist of a tumor microenvironment (TME) containing fibroblasts, immune cells, blood and lymphatic vessels, and the extracellular matrix. A …

de (code pays fourni par la source)

Data from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

Peter Horak, Christoph Heining, Simon Kreutzfeldt, Barbara Hutter et autres

Abstract The clinical relevance of comprehensive molecular analysis in rare cancers is not established. We analyzed the molecular profiles and clinical outcomes of 1,310 patients (rare cancers, 75.5%) enrolled in a prospective observational study by the German Cancer Consortium that applies whole-genome/exome …

de, us, lu (code pays fourni par la source)

Data from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

Peter Horak, Christoph Heining, Simon Kreutzfeldt, Barbara Hutter et autres

Abstract The clinical relevance of comprehensive molecular analysis in rare cancers is not established. We analyzed the molecular profiles and clinical outcomes of 1,310 patients (rare cancers, 75.5%) enrolled in a prospective observational study by the German Cancer Consortium that applies whole-genome/exome …

Supplementary Figures S1-S10 from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

Peter Horak, Christoph Heining, Simon Kreutzfeldt, Barbara Hutter et autres

This file contains supplementary figures S1-S10.